Trust facts

Important Information

We want to make investing with us simple and straightforward for all of our clients.

Please select your investor type from the options below.

Alternatively you can register or log in to an existing account.

Please note that by making your selection here you are agreeing to the Woodford Investment Management Ltd Privacy Statement and to our Terms and Conditions.

Woodford Patient Capital Trust plc

As at 31 January 2017

Home > Funds > WPCT > Trust facts

Trust nameWoodford Patient Capital Trust plc
Investment managerWoodford Investment Management Ltd
Investment objectiveTo achieve long-term capital growth through investing in a portfolio consisting predominantly of UK companies, both quoted and unquoted. The Company will aim to deliver a return in excess of 10% per annum over the longer term. (Note: this is a target only and not a profit forecast and there can be no assurance that it will be met.)
Independent board directorsSusan Searle (Chair)
Scott Brown
Steven Harris
Dame Pamela Louise Makin
Alan Hodson
Carolan Dobson
Total assets (GBP)£781.8m

Latest trust update

Patient Capital Trust update, January 2017

Mitchell Fraser-Jones 16 February 2017 7 min read

The Woodford Patient Capital Trust portfolio delivered a modestly positive return during the first month of 2017.

Read more

Performance

Performance summary
 1 month3 monthsYear-to-date1 yearSince launch
(21st April 2015)
Net asset value0.803.170.807.91-5.49
Ordinary share price1.103.781.104.13-8.00
Standardised performance (%)
 01/01/12 to
31/12/12
01/01/13 to
31/12/13
01/01/14 to
31/12/14
01/01/15 to
31/12/15
01/01/16 to
31/12/16
Net asset value-----3.53
Ordinary share price-----9.90

Past performance cannot be relied upon as a guide to future performance.
Source: Morningstar Direct on a total return basis, with net income reinvested.

Portfolio analysis

Top 10 holdings
NameIndustryWeight (%)
ProthenaHealth Care13.91
Oxford Nanopore (unquoted)Health Care7.63
Immunocore A (unquoted)Health Care5.56
PurplebricksFinancials5.10
Theravance BiopharmaHealth Care4.80
Proton Partners International (unquoted)Health Care4.38
Mereo BiopharmaHealth Care3.98
Oxford Sciences Innovation (unquoted)Financials3.50
Allied MindsFinancials3.39
4D PharmaHealth Care3.20
Total (of top 10) 55.45

View the full portfolio

Performance contribution

Performance contribution – 1 year to 31 March 2017

Sector allocation
IndustryWeight (%)
Health Care66.39
Financials26.23
Industrials7.75
Technology5.96
Telecommunications1.65
Consumer Goods0.70
Basic Materials0.44
Cash and near cash-9.12
Total100.00
Geographical allocation
CountryFund (%)
United Kingdom79.71%
United States22.44%
Norway3.30%
Ireland2.03%
Switzerland1.04%
Luxembourg0.60%
Maturity breakdown
Maturity stageWeight (%)
Mid/large cap22.44
Early growth35.66
Early stage51.02
Listing statusWeight (%)
Quoted61.73
Unquoted47.39

Prices and fees

Month-end prices As at 31 January 2017
 Price (p)
Market share price92.00p
Net asset value (Ex Income)94.51p
Net asset value (Cum Income)94.51p

View daily prices

Fees
Annual management feeNone
Performance fee15% of any excess returns over a 10% cumulative hurdle rate per annum, subject to a high watermark
Ongoing annual expenses0.1%

Latest news

    By using this website you are automatically agreeing to the Woodford Investment Management Ltd privacy statement